APPENDICES - NIHR Health Technology Assessment Programme
APPENDICES - NIHR Health Technology Assessment Programme
APPENDICES - NIHR Health Technology Assessment Programme
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
262<br />
Appendix 17<br />
Study details Population details Treatment details Results Interpretation<br />
Authors’ conclusions In poor<br />
surgical candidates with superficial<br />
oesophageal carcinoma PDT<br />
and EMR achieved outcomes<br />
comparable to oesophagectomy in<br />
good surgical candidates. PDT and<br />
EMR are reasonable alternatives to<br />
oesophagectomy for selected patients<br />
Brief study appraisal This small<br />
study was available only as an abstract<br />
and few methodological details were<br />
reported. The study populations for the<br />
different interventions did not appear<br />
to be comparable at baseline with PDT/<br />
EMR patients chosen if suboptimal for<br />
surgery. In addition no statistical tests<br />
were carried out to verify the findings,<br />
the results of this study may therefore<br />
not be reliable<br />
The authors’ conclusions do not follow<br />
from the results reported<br />
Mortality Not assessed<br />
Morbidity Eradication of lesions was<br />
achieved in 9/12 (75%) PDT, 5/6 (83%)<br />
EMR and 18/19 (95%) oesophagectomy<br />
patients<br />
QoL and return to normal activity<br />
Not assessed<br />
AEs Stricture occurred in 6/12<br />
(50%) PDT, 0/6 EMR and 10/19<br />
(53%) oesophagectomy patients.<br />
≥ 3 dilatations occurred in 4/12<br />
(33%) PDT, 0/6 EMR and 7/19 (37%)<br />
oesophagectomy patients. Other<br />
complications were reported for small<br />
numbers of patients<br />
Resource use Not assessed<br />
Trial treatments PDT vs EMR vs<br />
Oesophagectomy<br />
Intervention PDT: No details<br />
reported<br />
Comparator EMR: No details<br />
reported<br />
2nd comparator Oesophagectomy:<br />
No details reported<br />
Treatment intention<br />
Curative<br />
Type(s) of cancer<br />
and histology<br />
Superficial oesophageal<br />
cancer<br />
Main eligibility<br />
criteria Superficial<br />
oesophageal cancer<br />
determined by EUS<br />
and CT including HGD,<br />
carcinoma in situ or<br />
intramucosal carcinoma<br />
Patient<br />
characteristics Mean<br />
age: PDT, 76; EMR, 73;<br />
oesophagectomy, 65<br />
Thirty-six<br />
adenocarcinomas, one<br />
SCC<br />
Concomitant<br />
treatment Not stated<br />
Authors Scotiniotis et al.<br />
(2000) 110<br />
Data source Abstract<br />
Country USA<br />
Language English<br />
Study design Non-RCT<br />
No. of participants<br />
Total: 37<br />
Intervention: 12 (PDT)<br />
Comparator: Six EMR<br />
2nd Comparator: 19<br />
(oesophagectomy)<br />
No. of recruiting centres<br />
Not stated<br />
Follow-up period and<br />
frequency Mean FU 15 mth<br />
(range 2–28 mth). PDT and<br />
EMR patient FU 4–6 wk<br />
after treatment, then every<br />
3–6 mth; oesophagectomy<br />
patient FU dictated by<br />
symptoms<br />
EMR, endoscopic mucosal resection.